Evidence map›Paper›PMID 38379741›Full record

ArticleJournal of preventive medicine and hygiene2023

Risk factors for carbapenem-resistant

Ferhat Arslan, Ece Akbulut, Seniha Senbayrak, Asu Özgültekin, Sebahat Aksaray, Hayriye Cankar Dal, Hasan Oktay Emir, Handan Ankarali, Ali Mert, Haluk Vahaboglu

Open access · greenAbstract readMulticenter Study
In one paragraph

Article in Journal of preventive medicine and hygiene, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Determinants of Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026
    Article
  3. Enhancing the Antibacterial Activity of Endolysin againstJournal of microbiology and biotechnology · 2026
    Article
  4. Carbapenem-ResistantInfection prevention in practice · 2025
    Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Ferhat ArslanDepartment of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Istanbul Medeniyet University, Istanbul, Turkey.
Ece AkbulutDepartment of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Istanbul Medeniyet University, Istanbul, Turkey.
Seniha SenbayrakDepartment of Infectious Diseases and Clinical Microbiology, Hamidiye Medical Faculty, University of Health Sciences, Haydarpasa Numune Training and Research Hospital, Istanbul, Turkey.
Asu ÖzgültekinDepartment of Anesthesiology and Intensive Care, Hamidiye Medical Faculty, University of Health Sciences, Haydarpasa Numune Training and Research Hospital, Istanbul, Turkey.
Sebahat AksarayDepartment of Medical Microbiology, Hamidiye Medical Faculty, University of Health Sciences, Istanbul, Turkey.
Hayriye Cankar DalDepartment of Intensive Care, Health Sciences University, Ankara City Hospital, Ankara, Turkey.
Hasan Oktay EmirDepartment of Intensive Care, Health Sciences University, Ankara City Hospital, Ankara, Turkey.
Handan AnkaraliDepartment of Biostatistics, Faculty of Medicine, Istanbul Medeniyet University, Istanbul, Turkey.
Ali MertDepartment of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Istanbul Medipol University, Istanbul, Turkey.
Haluk VahabogluDepartment of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Istanbul Medeniyet University, Istanbul, Turkey.
Istanbul Medeniyet University · TRIstanbul Medipol University · TRSağlık Bilimleri Üniversitesi · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aim: This study investigated the risk factors for the development of carbapenem-resistant Klebsiella pneumoniae (CRKP) infections in adult patients in Intensive Care Units (ICUs). Methods: A multicentre case-control study was conducted in ICUs in three tertiary hospitals in Turkey. The cases were patients culture-confirmed CRKP and a condition associated with healthcare-associated infections. Two controls were randomly selected for each case from among all other patients with an ICU stay at least as long as that of the corresponding case-patient. A proportional semiparametric subdistribution hazards regression model was used to assess risk factors for CRKP infection. ICU discharge and non-CRKP-related deaths were treated as competing risks. Results: A total of 120 patients, 44 cases and 76 controls were included in the analysis. Of the controls, 32 were discharged from the ICU and 44 died without acquiring CRKP infection. Endotracheal intubation (hazard ratio [HR]: 1.96, 95% confidence interval [CI]: 1.00-3.868) and type 2 diabetes mellitus (HR: 1.57, 95% CI: 0.888-2.806) were associated with an increased risk of CRKP infection, whereas carbapenem exposure (HR: 0.47, 95% CI: 0.190-1.1175) and the presence of a nasogastric tube (HR: 0.49, 95% CI: 0.277-0.884) were associated with a decreased risk of CRKP infection. Conclusions: Enteral nutrition support via a nasogastric tube may be associated with a reduced risk of CRKP-resistant infections in ICU patients. This hypothesis should be tested with a well-designed study.

Indexed as

Diabetes Mellitus, Type 2Klebsiella InfectionsAdultAnti-Bacterial AgentsCarbapenemsCase-Control StudiesDrug Resistance, BacterialHumansIntensive Care UnitsKlebsiella pneumoniaeRetrospective StudiesRisk FactorsAnti-Bacterial AgentsCarbapenemsCarbapenem-resistant Klebsiella pneumoniae (CRKP) infectionsIntensive Care UnitsKlebsiella pneumoniaeRisk factors

Identifiers

PMID38379741
PMCPMC10876025
OpenAlexW4394760207

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.